

1 **Detection of SARS-CoV-2 infection by saliva and nasopharyngeal sampling in frontline**
2 **healthcare workers: an observational cohort study.**

3 Naomi F. Walker*^{1, 2}, Rachel L. Byrne*³, Ashleigh Howard¹, Elissavet Nikolaou¹, Madlen Farrar¹,
4 Sharon Glynn¹, Katerina S. Cheliotis¹, Ana I. Cubas Atienzar³, Kelly Davies¹, Jesus Reine¹, Zalina
5 Rashid-Gardner⁴, Esther L. German¹, Carla Solórzano¹, Tess Blandamer¹, Lisa Hitchins¹,
6 Christopher Myerscough¹, Brad Gessner⁵, Elizabeth Biegner⁵, Andrea M. Collins^{1,6,7}, Mike
7 Beadsworth², Stacy Todd^{2,8}, Helen Hill¹, Catherine F. Houlihan^{9,10}, Eleni Nastouli⁹ on behalf of the SAFER
8 investigators, Emily R. Adams³, Elena Mitsi^{5,1} and Daniela M. Ferreira^{5,1}.

9 ¹Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

10 ²Tropical and Infectious Diseases Unit, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

11 ³Centre for Drugs and Diagnostics, Tropical Disease Biology, Liverpool School of Tropical Medicine,
12 Liverpool, UK

13 ⁴NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospitals NHS
14 Foundation Trust, Liverpool, UK

15 ⁵Pfizer Vaccines, Collegeville, Pennsylvania, United States

16 ⁶National Institute for Health Research North West Coast, Liverpool, UK.

17 ⁷Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

18 ⁸Liverpool Health Partners, Liverpool, UK

19 ⁹Department of Clinical Virology, University College London Hospitals, UK

20 ¹⁰Department of Infection, Immunity and inflammation, University College London Great Ormond Street
21 Institute of Child Health, UK

22

23 **Running title: SARS-CoV-2 detection in healthcare workers.**

24 **Sources of funding:** Liverpool COVID-19 Partnership Strategic Research Fund to NFW; Pfizer

25 award to DF and EM (grant number WI2558862-1). The Medical Research Council

26 doctoral training partnership fund to RLB. CFH and EN received funding from MRC/UKRI

27 (SAFER study; grant number MC PC 19082)

28 **Conflicts of Interest:** The authors have no conflicts of interest to declare.

29 **Corresponding author:** Naomi F. Walker, Liverpool School of Tropical Medicine, Liverpool UK, E-

30 mail: Naomi.Walker@lstmed.ac.uk phone number: +44 (0) 151 705 3100

31 ***Authors contributed equally.**

32 [§] Joint senior authors

33 **Word count:** Abstract, XX; Manuscript, XX

34 **Authors' contributions:** CH, DF, EA, E Nastouli, E Nikolaou, EM, HH, MB, NFW, RLB, ST designed

35 the study. AC, AH, AMC, ELG, HH, KC, KD, MF, NFW, SG, ZRG recruited the clinical cohort. AH,

36 AICA, CM, CSG, DF, EA, E Nikolaou, EM, JR, KC, LH, MF, NFW, RLB, TB managed data and

37 performed analysis. The initial draft manuscript was prepared by NFW, RLB and EM. All authors

38 reviewed and approved the final manuscript.

39 **Keywords:** Healthcare worker, SARS-CoV-2, COVID-19, coronavirus, pandemic, diagnostics

40

41 **Abstract (250 words)**

42 *Background*

43 The SARS-CoV-2 pandemic has caused an unprecedented strain on healthcare systems
44 worldwide, including the UK National Health Service (NHS). During the first wave of SARS-CoV-2
45 transmission in UK, SARS-CoV-2 NHS diagnostic test availability was limited to self-isolating
46 symptomatic staff. The burden of symptomatic and asymptomatic infection in healthcare
47 workers (HCW) attending work was unknown.

48 *Methods*

49 We conducted an observational cohort study of SARS-CoV-2 infection in HCW working in an acute
50 NHS Trust during the first wave of the COVID-19 pandemic, using serial self-collected saliva and
51 nasopharyngeal (NP) samples. We also collected self-assessed symptom profiles and isolation
52 behaviours. We retrospectively compared SARS-CoV-2 detection by RT-PCR from saliva (weekly)
53 and NP swabs (twice weekly) from 85 individuals in this cohort and evaluated the association
54 with symptoms.

55 *Findings*

56 Over a 12-week period from 30th March 2020, 40% (n=34/85, CI95% 31.3-51.8%) HCWs had
57 evidence of SARS-CoV-2 infection by surveillance NP swab and/or saliva RT-qPCR. Agreement
58 between paired saliva and NP swabs was poor (28.6%, CI95% 13.2-48.7%) with both methods
59 detecting symptomatic and asymptomatic infections. Symptoms were reported by 47.1% (n=40)

60 and self-isolation by 25.9% participants (n=22). Only 41.2% (n=14/34) participants with SARS-
61 CoV-2 infection reported any symptoms within 14 days of the infection.

62 *Interpretation*

63 HCWs are a potential source of SARS-CoV-2 transmission in hospitals and symptom screening will
64 identify the minority of infections in HCW. Saliva is an easily accessible fluid sample for screening
65 for SARS-CoV-2 infection and in addition to NP swab, facilitated ascertainment of symptomatic
66 and asymptomatic cases in this setting. Combined saliva and NP testing would improve detection
67 of SARS-CoV-2 for surveillance. Better understanding of transmissibility from asymptomatic staff
68 using transmission-based infection precautions, is required to inform policy.

69

70

71

72

73

74 Introduction

75 The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of the
76 coronavirus disease 2019 (COVID-19) pandemic, has caused an unprecedented strain on health
77 systems worldwide, including in the United Kingdom National Health Service (NHS) and the
78 frontline healthcare workers (HCW) it employs. HCWs are particularly vulnerable to SARS-CoV-2
79 infection due to their frequent close proximity to infectious COVID-19 patients (Korth *et al.*,
80 2020). The risk of transmission of SARS-CoV-2 from infected HCW to their patients and colleagues
81 whilst attending work was also recognized as a major threat to infection prevention and control.
82 Transmission-based precautions (including PPE) were implemented widely, for the protection of
83 the staff and their patients.

84 The global SARS-CoV-2 pandemic response has been hindered by inadequate access to
85 diagnostics. Whilst reverse transcription polymerase chain reaction (RT-qPCR) assays for SARS-
86 CoV-2 on respiratory samples have proven the mainstay of clinical diagnosis, in the early stages
87 of the pandemic, testing capacity was extremely limited, and was initially reserved only for
88 hospitalised individuals meeting the COVID-19 case definition. The UK COVID-19 case definition
89 evolved during the outbreak, losing the initial geographic restrictions on 12th March 2020 as
90 transmission became widespread (see Box 1). Loss of taste and smell was added as a symptom
91 to the case definition in May 2020. With coordinated national and global efforts, diagnostic
92 testing capacity has been scaled up, substantially. Currently, regular asymptomatic screening of
93 HCW is standard practice in the NHS utilizing both respiratory swabbing and saliva, however,
94 there has not been consensus on the optimal frequency or sample type.

Box 1 UK COVID-19 Case Definitions

Stay at home guidance (for HCW & public)*

(issued by Chief Medical Officer, 12th March 2020):

- a. A new continuous cough OR
- b. High temperature (of 37.8 degrees centigrade or higher)

regardless of travel history or contact with confirmed cases.

Current UK government testing advice

(from <https://www.gov.uk/coronavirus>, accessed 12th January 2021):

If you have any coronavirus symptoms:

- a high temperature
- a new, continuous cough
- a loss of, or change to, your sense of smell or taste**

Get a test and stay at home

95

*initially for a minimum of 7 days as no community or occupational testing was available

** introduced into the case definition from 18th May 2020

97

98 SARS-CoV-2 Acquisition in Frontline Health Care Workers – Evaluation to Inform Response
99 (SAFER) was a cohort study designed to prospectively collect data on infections in HCW from
100 March – July 2020, in order to inform control strategies in healthcare settings. In this
101 retrospective analysis of a subgroup of SAFER Liverpool participants, we evaluated the
102 prevalence of SARS-CoV-2 RNA detected by weekly saliva or twice weekly nasopharyngeal (NP)
103 self-testing by RT-qPCR, and the occurrence of symptoms of infection. Laboratory analysis was

104 not conducted in real time and HCW followed national guidance for isolation based on symptoms.
105 We and others have previously demonstrated the utility of saliva as a reliable alternative to nasal
106 swabbing for the detection of SARS-CoV-2 in symptomatic individuals (Anne L. Wyllie *et al.*, 2020;
107 Byrne *et al.*, 2020; Thompson and Cunniffe, 2020; Bastos *et al.*, 2021). We compare SARS-CoV-2
108 detection by RT-qPCR in saliva and nasopharyngeal swabs collected routinely in a mixed cohort
109 of symptomatic and asymptomatic healthcare workers and report the association with symptom
110 profiles.

111 **Methods**

112

113 *Ethics*

114 Ethical approval was obtained from the NHS Health Research Authority (ref 20/SC/0147). All
115 participants provided written informed consent.

116

117 *Participant recruitment and involvement*

118 Participants were healthcare workers in a variety of roles who enrolled onto the SAFER Study
119 between 30th March and 9th April 2020 at Royal Liverpool University Hospital (RLUH), Liverpool
120 University Hospitals NHS Foundation Trust. Eligible individuals were at least 18 years old and
121 were working in a patient facing role for at least five hours for at least one day during the study
122 period (12 weeks from enrolment). Participants were invited from areas caring for COVID-19
123 patients (Accident and Emergency (A/E), the acute medical unit, infectious diseases and
124 respiratory wards), and areas which aimed to be COVID-19 free (haematology, surgical wards).

125 Participants were free to withdraw from the study at any point and could choose to either allow
126 their existing data to remain in the study or be excluded. Inclusion in this subgroup analysis
127 required the participant to have provided saliva samples.

128

129 *Sample collection*

130 Participants were asked to provide a self-collected NP sample by swabbing the throat and then
131 nose twice weekly when attending work. Swabs were transported in 1ml of liquid amies (MWE,
132 UK) to designated collection points within the hospital by participants and then transported to
133 the laboratory daily by the research team, where they were stored at -80°C, until further analysis.
134 Saliva (at least 500µl) was collected once per week into a sterile tube (SARSTEDT, USA) by passive
135 drool using a plastic funnel at home. Participants were asked to store saliva samples in their home
136 freezers (approximately -20°C) before transportation in cooler packs (provided by the research
137 team) to the Liverpool School of Tropical Medicine (LSTM) laboratories for processing at monthly
138 intervals. Participants were instructed not to collect NP samples during periods of self-isolation,
139 however, they continued to collect weekly saliva samples during this time.

140

141 *RNA extraction*

142 Viral RNA from NP swabs was extracted using the high-throughput Quick DNA/RNA™ viral
143 MagBead kit (Zymo, USA), whereas viral RNA from saliva was extracted using the QIAamp Viral
144 RNA Mini Kit (Qiagen, Germany), following in-house optimisation. Both followed manufacturer's

145 instructions and an internal extraction control incorporated at the lysis stage (Genesig, UK). Once
146 extracted, samples were taken immediately for downstream application and stored on ice during
147 RT-qPCR setup.

148

149 *SARS-CoV-2 RT-qPCR*

150 For SARS-CoV-2 RT-qPCR detection, 8µl of extracted RNA was tested using the Genesig® Real-
151 Time Coronavirus COVID-19 PCR assay (Genesig, UK) in a RGQ 6000 thermocycler (Qiagen,
152 Germany). Samples were classified as RT-qPCR positive if both the internal extraction and the
153 SARS-CoV-2 probes were detected at <40_{Ct}. Genome copy numbers per ml (gcn/ml) were
154 quantified using the manufacturer's positive control (1.67 x 10⁵ gcn/µl) as a reference for
155 threshold. Samples with invalid RT-qPCR internal extraction amplification results were re-
156 extracted and re-run.

157

158 *Analytical sensitivity*

159 The analytical sensitivity of saliva compared to NP swabs was compared by spiking the samples
160 with serial dilutions of SARS-CoV-2 culture supernatant. The isolate
161 REMRQ0001/human/2020/Liverpool propagated in VERO E6 cells and maintained as previously
162 described (Patterson *et al.*, 2020) was used for the serial dilutions. Fourteen NP swabs were
163 stored in 1ml of amies preservation medium (Copan, Italy) and 4ml of saliva were self-collected
164 from a confirmed RT-qPCR SARS-CoV-2 negative volunteer. A serial dilution series of SARS-CoV-2

165 ranging from 10^6 to 10^{-6} plaque forming units per ml (pfu/ml) was used to spike 140 μ l of saliva
166 and swab samples. The limit of detection (LOD) was determined by the lowest concentration for
167 which all three RT-qPCR replicates amplified. For quantification of the gcn/ml, viral RNA of the
168 serial dilutions was extracted using QIAmp Viral RNA mini kit (Qiagen, Germany) and the gcn/ml
169 were calculated using the COVID-19 Genesig RT-qPCR kit (PrimerDesign, UK) with a ten-fold serial
170 dilution of quantified specific in vitro-transcribed RNA (Genesig, UK).

171

172 *Symptom reporting, isolation and diagnostic tests*

173 Symptom reporting was via a short questionnaire that was completed twice weekly,
174 accompanying each sampling episode; participants could select from COVID-19 case definition
175 symptoms and other acute respiratory illness symptoms or enter other symptoms in free text.
176 At the time of the study, SARS-CoV-2 testing of staff who did not meet the UK COVID-19 case
177 definition (Box 1) was not routine, nor feasible due to lack of laboratory capacity and testing
178 reagents. Participants with symptoms that met the COVID-19 case definition were advised to self-
179 isolate and seek COVID-19 diagnostic testing via the staff testing service when it became available
180 but also continued study procedures, except for self NP collection during periods of self-isolation.
181 Periods of self-isolation and standard-of-care test results were reported by participants to the
182 research team and recorded. Symptoms associated with each sample collected were scored on a
183 scale from 0 (no symptoms) to 6 (multiple symptoms consistent with the COVID-19 case
184 definition) for the purposes of analysis (see Box 2). Participants were assigned the highest code
185 for which they qualified.

186
187 Study samples were stored until the end of the study follow up period, and laboratory testing for
188 SARS-CoV-2 infection was retrospective. Results were made available to participants after the
189 laboratory analysis was complete.
190

Box 2 Symptom scores assigned for symptom and isolation status	
0	Asymptomatic
1	Symptom (s), likely unrelated e.g. ankle pain
2	Symptom (s), non-specific e.g. Fatigue / headache / muscle aches
3	One respiratory symptom, not COVID case definition e.g. Cough (other), sore throat, coryza
4	More than one symptom including a respiratory symptom (not COVID-19 case definition symptom)
5	COVID-19 case definition symptom: New/continuous cough or fever or loss of taste/smell
6	More than one COVID-19 case definition symptom: new/continuous cough, fever, loss of taste or smell

191
192 *Statistical analysis*
193 Analysis was in R (version 4.0.4) and Prism 8 (Graphpad). Two-tailed statistical tests was used to
194 compare variables throughout the study. Non-parametric Mann-Whitney test was used to

195 compare two groups. Correlations were assessed using Spearman's correlation test using raw,
196 non log-transformed values.

197

198 **Results**

199 *Participants and follow up*

200 In total, 99 participants were enrolled into the SAFER Liverpool cohort. Of these, 85 participants
201 provided both saliva and NP samples over 8 and 12 weeks respectively and are therefore included
202 in this analysis. Participant characteristics are reported in Table 1. The majority (77.6%, n=66)
203 were female. Participants comprised doctors, nurses, healthcare assistants and allied health
204 professionals (physiotherapists and occupational therapists). Retention in follow up was 84.7%,
205 (n=72) participants at four weeks, 81.2% (n=69) participants at eight weeks and 74.1% (n=63)
206 (74.1%) participants at twelve weeks. A median of 21 NP swabs (interquartile range (IQR) 10.5-
207 24.0) of a target of 24 and 8 saliva samples (IQR 4.50-8.00) of a target of 8 were submitted per
208 participant.

209

210 **Table 1. Participant characteristics**

211

Total included participants (n)	85
Female, n (%)	66 (77.6)
Age, median years (IQR)	35.0 (27.5-46.5)
Role, n (%)	
Doctor	35 (41.2)
Nurse	32 (37.6)
Health Care Assistants	9 (10.6)
Allied health professional	6 (7.1)
Other	3 (3.5)
Experienced symptoms*, n (%)	
Any	40 (47.1)
COVID-19 case definition	9 (10.6)
Isolated during study period, n (%)	22 (25.8)
COVID-19 diagnosis during study**	3
COVID-19 hospitalisation	0

212

213 *Over 12 weeks study period

214 **outside of the study setting

215

216

217

218 *COVID-19 diagnosis, symptoms and isolation status*

219

220 Of the 85 participants, 40.0% (n=34, CI95% 31.3-51.8%) were positive for SARS-CoV-2 RNA on at
221 least one study sample during the study period. Symptoms of any kind were reported by 47.1%
222 (n=40) participants on twice weekly questionnaires during study follow up whilst attending work.
223 However, only 41.2% (n=14/34) participants with SARS-CoV-2 RNA detected by SAFER study
224 sampling reported symptoms within a 14-day period either side of their positive result (Table 2).
225 In participants with evidence of SARS-CoV-2 infection attending work, symptoms were
226 predominantly respiratory (coryza, sore throat, cough) but most often not those compatible with
227 the COVID-19 case definition.

228

229

230 **Table 2 Symptoms reporting in SARS-CoV-2 RNA positive participants during study follow up**

231 (excluding participants who were self-isolating for COVID-19 case definition symptoms)

Participants with positive results (NP swab or saliva), n	34
Participants with symptoms associated with positive result*, n (% positive participants)	14 (41.2)
Fever	0 (0)
New continuous cough	0 (0)
Cough, other	6 (23.6)
Rhinorrhoea	8 (23.5)
Muscle aches	1 (2.9)
Joint Pain	2 (5.9)
Sore Throat	5 (14.7)
Headache	4 (11.8)
Chest Pain	0
Breathing Difficulty	0
Change in Taste or Smell**	5 (14.7)

232

233

*within 14 days of positive result

234

**at any time during study follow up

235

236 The timing of SARS-CoV-2 RNA detection and relationship with symptoms and self-isolation is

237 shown in Figure 1. Most positive results were detected in the early weeks of the study period,

238 which commenced shortly after the first national lockdown was declared (23rd March 2020) and

239 prior to universal use of face masks/coverings at all time for staff in hospital (introduced on 15th
240 June 2020). Nine participants reported symptoms consistent with the COVID-19 case definition
241 and 14 participants reported COVID-19 testing during the 12-week period, of which only 3
242 participants received a confirmed diagnosis of COVID-19 by qPCR of a nose/throat sample, for
243 clinical purposes outside of the study setting. Periods of self-isolation were prevalent, reported
244 by 25.9% (n=22/85) participants. In 7 incidences, self-isolation was reportedly due to a contact
245 rather than due to symptoms. Eight participants who self-isolated tested positive for SARS-CoV-
246 2 RNA on study samples. Only 10/34 participants who were SARS-CoV-2 RNA positive self-isolated
247 at any point during the study. The median duration of isolation per participant was 6.5 (IQR 5.0-
248 14.0) days.


249

250

251

252

253



275

276 **Figure 1 Symptoms, isolation and SARS-CoV-2 RNA status in HCW (n=85) over a period of 12 weeks.**

277 Heatmap for recorded symptoms using a colour scale to represent symptoms score (see Box 2) from grey
278 (0: Asymptomatic) to red (5: a symptom consistent with the COVID-19 case definition in red). No
279 participants scored 6. The participant with symptoms recorded at every timepoint experienced loss of
280 smell which persisted throughout the study period. Isolation period is by a black box delineating
281 timepoints. Participants were clustered into two groups, nCoV+ (positive for SARS-CoV-2 RNA by either
282 diagnostic method), or nCoV- (SARS-CoV-2 RNA negative on results available). Time points with missing
283 data are shown in white.

284

285 *Analytical sensitivity*

286 The analytical sensitivity in spiked samples indicated the LOD for saliva was 10^{-2} pfu/ml ($\approx 2.0 \times$
287 10^1 gcn/ml) and for the NP swabs 10^0 pfu/ml ($\approx 2.0 \times 10^3$ gcn/ml). However, amplification of one
288 or more replicates was recorded for saliva and NP swabs to concentrations 10^{-6} (pfu/ml) and 10^{-
289 4 (pfu/ml), respectively.


290

291 *Comparison of saliva and NP swab for detection of SARS-CoV-2 infection by qPCR*

292

293 SARS-CoV-2 RNA was detected in 3.02% (n=43/1425) NP samples and 4.15% (n=22/530) saliva
294 samples (Figure 2). Overall, 8 participants were positive for SARS-CoV-2 RNA on both NP swab
295 and saliva, 17 participants were positive by NP swab only and 9 participants by saliva only.
296 Reports of symptoms within 14 days of a positive result were similar in participants who were
297 positive by NP swab compared to saliva (44.0%, (n=11/25) and 40.0% (n=8/16) respectively,
298 $p=0.757$). The median viral load in SARS-CoV-2 RNA positive participants with symptoms was 139
299 gcn/ml- (IQR: 31-3332 gcn/ml) and without symptoms was 64.4 gcn/ml (IQR: 25.1- 494.5 gcn/ml),
300 $p=0.65$. No correlation was found between viral loads and assigned symptom score ($r=-0.12$, $p=$
301 0.52).

302



303

304 **Figure 2 SARS-CoV-2 RNA detection by saliva and nasopharyngeal (NP) swab during study period.**

305 Timing of SARS-CoV-2 positivity by NP swab and saliva sample over a period of 12- and 8-weeks,
 306 respectively, in SARS-COV-2 RNA positive (nCoV+) participants, clustered by symptom status
 307 (symptomatic or asymptomatic). **A)** Heatmap of log10 viral load value per NP swab sample over
 308 surveillance period of 12 weeks (n= 25 nCoV+ by NP swab, 15 symptomatic and 10 asymptomatic). **B)**
 309 Heatmap of log10 viral load value per saliva sample over the sampling period of 8 weeks (n=17 nCoV+,
 310 11 symptomatic and 6 asymptomatic).

311

312 *The agreement of saliva and NP swabs for SARS-CoV-2 detection in a paired sample cohort*

313 We then investigated the agreement of NP swabs and saliva for SARS-CoV-2 detection, utilizing
 314 paired samples where both saliva and NP samples had been self collected on the same date. A
 315 total of 225 paired samples were collected, of which 20 (8.89%) included a SARS-CoV-2 RNA
 316 positive result. This comprised 12 positive NP samples and 13 positive saliva samples. Of these,
 317 7 were positive exclusively by NP swab and 8 exclusively by saliva. In only 5 paired samples were

318 the NP and saliva result both positive. There was no significant difference between viral loads for
319 either specimen ($p=0.312$) as shown in figure 3. For SARS-CoV-2 RNA positive individuals with
320 paired samples, this resulted in 35.0% ($n=7/20$) positive only by NP swab, 40.0% ($n=8/20$) positive
321 only by saliva and 25.0% ($n=5/20$) consistently positive for both specimens. This produced an
322 estimated prevalence in this paired sample subgroup of 73.5% and 50.0% for NP swabs and saliva
323 respectively, comprising samples from 83 individuals. The proportion positive agreement of
324 saliva and NP swabs was 40.0% with an overall agreement of 93.3%.

325

326

327

328


329

330

331

332

333



334

335 **Figure 3 Comparison of SARS-CoV-2 viral load in paired nasopharyngeal swab and saliva**
336 **samples.**

337 The logged viral load of paired saliva and nasopharyngeal (NP) swabs (n=20) from healthcare
338 workers for the first 8 weeks of the study period is shown. Paired samples were those where the
339 participant self-collected both saliva and NP swab on the same date. Data points for a single
340 sample are represented by a point outlined by a circle and a single line connects paired samples.
341 Boxes represent interquartile range (IQR) with a median central line.

342

343

344

345 Discussion

346 Here, we describe a cohort of 85 frontline HCW in Liverpool and present results of surveillance
347 NP swabs and saliva samples for SARS-CoV-2 infection, for up to 12 weeks during the first peak
348 of COVID-19 pandemic. A high proportion (40%) of frontline healthcare workers had evidence of
349 SARS-CoV-2 infection during study follow up. Most infections occurred early in the follow up
350 period, likely reflecting transmission prior to community interventions and widespread use of
351 transmission-based precautions in hospital. This supports findings from other UK healthcare
352 settings demonstrating a high prevalence of SARS-CoV-2 infection in HCW in the NHS in Spring
353 2020 (Houlihan *et al.*, 2020; Keeley *et al.*, 2020; Treibel *et al.*, 2020).

354

355 We report poor agreement between saliva and NP swabs for the detection of SARS-CoV-2. This
356 is consistent with reports by Rao *et al.*, (2020) in asymptomatic adult males detained in a COVID
357 detention centre, where exposure to SARS-CoV-2 is presumed to be high. Most other data
358 pertaining to the performance of saliva for SARS-CoV-2 diagnosis is derived from symptomatic
359 individuals, with numerous studies reporting good concordance (Wyllie *et al.*, 2020a, 2020b;
360 Byrne *et al.*, 2020), as also reported by Lee *et al.* (2020), in a recent systematic review combining
361 37 studies of which the majority of participants were symptomatic, where a small difference
362 between the sensitivity of saliva and NP swabs (-3.4% (95% CI -9.9 to 2.1%)) was found.
363 Interestingly, here we report from spiked saliva samples, that SARS-CoV-2 can be detected with
364 greater sensitivity in saliva compared to NP swabs by 100- fold. As we continue to see SARS-CoV-
365 2 cases reduce it will be important to quickly and accurately detect asymptomatic cases in the

366 community. It is important to note that in our paired analysis, 26% (n=9) SARS-CoV-2 infections
367 were missed by NP swabs and thereby saliva should still be considered an alternative to more
368 invasive, more costly swabbing (Bastos *et al.*, 2021). This study supports the use of saliva in
369 addition to NP sampling for optimal detection of infection.

370
371 This dataset is unique in including both regular saliva analysis and NP swabbing into a HCW
372 surveillance study. As routine asymptomatic staff testing was not available during the study
373 period and laboratory capacity at the time did not permit contemporaneous analysis, the study
374 results were not available until after the study period and therefore did not influence participant
375 symptom reporting or self-isolation behavior. A minority of symptomatic participants with SARS-
376 CoV-2 infection met the COVID-19 case definition. A large proportion (58.8%) of SARS-CoV-2
377 infections detected in this HCW cohort were asymptomatic. This is considerably higher than
378 predicted from a recent systematic review and meta-analysis which found that the minority of
379 infections were asymptomatic (estimated 20%, 95% confidence interval 17-25) (Buitrago-Garcia
380 *et al.*, 2020).

381
382 Regular screening of HCW, irrespective of symptoms has now been implemented in UK as an
383 intervention to control SARS-CoV-2 transmission in hospitals and other healthcare settings.
384 However, the impact of this policy in terms of staff absences and the potential indirect
385 consequences for the healthcare system has not yet been realised. Transmission from
386 asymptomatic individuals may be low, especially if these individuals are trained in transmission-

387 based precautions and are using appropriate PPE (Buitrago-Garcia *et al.*, 2020; Madewell *et al.*,
388 2020). Poor staffing levels in acute settings may pose a risk to patients and may increase the
389 psychological burden on staff. It is essential to gain further data on the transmissibility of
390 asymptomatic infection in this context to fully appreciate the risk-benefit of intensive HCW
391 surveillance interventions (Gandhi, Yokoe and Havlir, 2020; Pollock and Lancaster, 2020).

392

393 Finally, we note that HCW did not consistently self-isolate when respiratory symptoms were
394 experienced. Resource limitations reducing access to routine diagnostic testing possibly
395 impacted on staff isolation and test-seeking behaviour in the first wave of the UK COVID-19
396 pandemic. Occupational testing first became available to symptomatic HCW at Liverpool
397 University Hospitals NHS Foundation Trust on 2nd April 2020. However, presenteeism in HCW may
398 be a contributory factor, even in the context of a global respiratory pandemic (Tartari *et al.*,
399 2020). Clarification on and reinforcement of self-isolation and testing policies for HCW when
400 symptomatic is advisable, especially given symptomatic infections are likely more transmissible
401 (Buitrago-Garcia *et al.*, 2020).

402

403 Limitations of this study include some loss to follow up and withdrawal of participants with
404 resulting missing data. However, the overall retention in the study was good (over 80% at week
405 8) and return of samples was overall high. There was possible inconsistency of self-sampling
406 technique as participants were not supervised. Sample processing, which required one freeze-

407 thaw cycle (NP swab) or two freeze-thaw cycles (saliva) prior to RNA extraction, possibly reduced
408 the overall yield of the PCR assay.

409

410 In summary, we report a high prevalence of SARS-CoV-2 infection in asymptomatic and
411 symptomatic HCWs, attending work during the first wave of the COVID-19 pandemic in UK, as
412 detected by saliva and NP surveillance sampling. However, there was limited agreement between
413 the two sampling methods. Detection of SARS-CoV-2 by surveillance sampling far exceeded case
414 detection by routine diagnostic testing (targeted to those with symptoms) and the majority of
415 infections were asymptomatic. This study supports the use of saliva as an additional sample for
416 screening for SARS-CoV-2 infection, in order to optimize case detection of symptomatic and
417 asymptomatic infections. Saliva PCR should therefore be considered in addition to NP PCR for
418 SARS-CoV-2 detection, where high sensitivity screening is required.

419

420

421

422

423

424 Acknowledgements

425 We acknowledge and thank the participants of the SARS-CoV-2 Acquisition in Frontline Health Care
426 Workers – Evaluation to Inform Response. We also acknowledge the valuable contributions of LSTM
427 Accelerator Research Clinic staff and volunteers, and LUHFT Clinical Research Unit team who supported
428 the follow up of participants. We thank Natalie Tate and Sherin Pojar for excellent technical and
429 logistical support and Saigini Vickneswaran and Chiamaka Sophie Njoku for support with data
430 management. We thank Dr Ghaith Aljayyousi for assistance with R code. We acknowledge and thank
431 University College London Hospitals NHS Foundation Trust for sponsorship of the study. N.F.W was funded by
432 the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and
433 Zoonotic Infections, the Centre of Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey
434 Charity. D.F and E.M received funds from Pfizer grant no. WI255862, for this study. We also acknowledge
435 support of Liverpool Health Partners and the Liverpool-Malawi-COVID-19 Consortium.

436 SAFER Investigators: Jude Heaney, Matt Byott, Dan Frampton, Moira Spyer, Sarah Edwards, Andrew
437 Hayward, Richard Gilson, Ed Manley, Susan Michie, Catherine Houlihan, Eleni Nastouli

438

439

440

441 **References**

- 442 Bastos, M. L. *et al.* (2021) 'The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With
443 Saliva Versus Nasopharyngeal Swabs', *Annals of Internal Medicine*, pp. M20-6569. doi:
444 10.7326/M20-6569.
- 445 Buitrago-Garcia, D. *et al.* (2020) 'Occurrence and transmission potential of asymptomatic and
446 presymptomatic SARSCoV-2 infections: A living systematic review and meta-analysis', *PLoS*
447 *Medicine*. Public Library of Science, p. e1003346. doi: 10.1371/journal.pmed.1003346.
- 448 Byrne, R. L. *et al.* (2020) 'Saliva alternative to upper respiratory swabs for SARS-CoV-2
449 diagnosis', *Emerging Infectious Diseases*, 26(11), pp. 2769–2770. doi: 10.3201/eid2611.203283.
- 450 Cohen, J. and Rodgers, Y. van der M. (2020) 'Contributing factors to personal protective
451 equipment shortages during the COVID-19 pandemic', *Preventive Medicine*. Academic Press
452 Inc., p. 106263. doi: 10.1016/j.ypmed.2020.106263.
- 453 Dyer, C. (2020) 'Covid-19: doctors are warned not to go public about PPE shortages', *BMJ*
454 *(Clinical research ed.)*, 369, p. m1592. doi: 10.1136/bmj.m1592.
- 455 Gandhi, M., Yokoe, D. S. and Havlir, D. V. (2020) 'Asymptomatic Transmission, the Achilles' Heel
456 of Current Strategies to Control Covid-19', *New England Journal of Medicine*, 382(22), pp. 2158–
457 2160. doi: 10.1056/nejme2009758.
- 458 Houlihan, C. F. *et al.* (2020) 'Pandemic peak SARS-CoV-2 infection and seroconversion rates in
459 London frontline health-care workers', *The Lancet*. Lancet Publishing Group, pp. e6–e7. doi:
460 10.1016/S0140-6736(20)31484-7.

- 461 Keeley, A. J. *et al.* (2020) 'Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS
462 Foundation Trust in the United Kingdom, March 2020', *Eurosurveillance*, 25(14), p. 2000433.
463 doi: 10.2807/1560-7917.ES.2020.25.14.2000433.
- 464 Korth, J. *et al.* (2020) 'SARS-CoV-2-specific antibody detection in healthcare workers in Germany
465 with direct contact to COVID-19 patients.', *Journal of Clinical Virology*, 128(January).
- 466 Lee, R. A. *et al.* (2020) 'Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-
467 CoV-2 molecular detection: A systematic review and meta-analysis', *medRxiv*, pre-print, p.
468 2020.11.12.20230748. Available at:
469 <http://medrxiv.org/content/early/2020/11/13/2020.11.12.20230748.abstract>.
- 470 Madewell, Z. J. *et al.* (2020) 'Household Transmission of SARS-CoV-2: A Systematic Review and
471 Meta-analysis', *JAMA network open*, 3(12), p. e2031756. doi:
472 10.1001/jamanetworkopen.2020.31756.
- 473 Patterson, E. I. *et al.* (2020) 'Methods of inactivation of SARS-CoV-2 for downstream biological
474 assays.', *bioRxiv : the preprint server for biology*, p. 2020.05.21.108035. doi:
475 10.1101/2020.05.21.108035.
- 476 Pollock, A. M. and Lancaster, J. (2020) 'Asymptomatic transmission of covid-19', *The BMJ*. BMJ
477 Publishing Group. doi: 10.1136/bmj.m4851.
- 478 Rao, M. *et al.* (2020) 'Comparing nasopharyngeal swab and early morning saliva for the
479 identification of SARS-CoV-2', *Clinical Infectious Diseases*. doi: 10.1093/cid/ciaa1156.
- 480 Tartari, E. *et al.* (2020) 'Not sick enough to worry? "Influenza-like" symptoms and work-related

481 behavior among healthcare workers and other professionals: Results of a global survey', *PLOS*
482 *ONE*. Edited by M. Katz, 15(5), p. e0232168. doi: 10.1371/journal.pone.0232168.

483 Thompson, R. N. and Cunniffe, N. J. (2020) 'The probability of detection of SARS-CoV-2 in saliva',
484 *Statistical Methods in Medical Research*. SAGE Publications Ltd, pp. 1049–1050. doi:
485 10.1177/0962280220915049.

486 Treibel, T. A. *et al.* (2020) 'COVID-19: PCR screening of asymptomatic health-care workers at
487 London hospital', *The Lancet*. Lancet Publishing Group, pp. 1608–1610. doi: 10.1016/S0140-
488 6736(20)31100-4.

489 Wyllie, Anne Louise *et al.* (2020a) 'Saliva is more sensitive for SARS-CoV-2 detection in COVID-
490 19 patients than nasopharyngeal swabs'. doi: 10.1101/2020.04.16.20067835.

491 Wyllie, Anne Louise *et al.* (2020b) 'Saliva is more sensitive for SARS-CoV-2 detection in COVID-
492 19 patients than nasopharyngeal swabs', *Camila Odio* 8, 3, p. 12. doi:
493 10.1101/2020.04.16.20067835.

494 Wyllie, Anne L. *et al.* (2020) 'Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-
495 CoV-2', *New England Journal of Medicine*, 383(13), pp. 1283–1286. doi:
496 10.1056/nejmc2016359.

497

498

499

500